Relationship Between HPV Type 16 in the Cervix and Intraepithelial Neoplasia
Relationship Between HPV Type 16 in the Cervix and Intraepithelial Neoplasia
Abstract & Commentary
Synopsis: Women with persistent Human Papillomavirus Type 16 infection are more likely to develop cervical intraepithelial neoplasia than those with transient infection.
Source: ter Harmsel B, et al. Obstet Gynecol 1999; 93:46-50.
In their introduction, ter hamsel and associates point out that the data that have previously been published concerning the development of cervical intaepithelial neoplasia and the presence of Human Papilomavirus Type 16 (HPV Type 16) viral infection are "not straightforward." Although a large number of women are known to be infected with the virus, few HPV 16-infected women ever develop neoplasia. The purpose of this study was to determine whether there was an association between the persistence of an HPV 16 infection and the later development of CIN.
At the hospital of ter Harmsel et al, all women who had Pap smears performed in the gynecology department during the years 1988 and 1989 also had screening for HPV 16 infection using PCR technology. Those women who had a positive screen for HPV 16 and had a normal smear were asked to return at six-month intervals for repeat testing. After three consecutive tests had been performed, the study participants were divided into those who had three consecutive HPV 16-positive tests and those who did not.
Of the 5500 women who were screened, 110 (2%) were found to be HPV 16-positive. Thirty-two of these women had an abnormal Pap smear and were excluded. Fifty-four of the remaining 78 women consented to be part of the study. Twenty-five of these 54 had persistent infections, and 29 did not. Eleven of the twenty-five (44%) women with persistent infections developed CIN, whereas only six of the 29 (21%) women who had transient infections did so (P = 0.036). The CIN in those women with persistent infection tended to be more advanced.
In the discussion section of the paper, ter Harmsel et al suggest that women who have positive HPV 16 tests should be monitored "more closely" because of their increased risk of developing CIN. They further suggest that the routine use of HPV testing would not be cost- effective, even though they used a low estimate of the cost of each HPV test. ter Harmsel et al suggest that women with (atypical squamous cell of undetermined significance) smears might represent a sub-group for whom HPV 16 testing might be cost-effective, but their study did not address this issue.
Comment by Kenneth Noller, MD
Considerable discussion occurs at every cytology meeting, colposcopy meeting, and constantly in the literature regarding the role of HPV testing. There is no doubt that those women who are infected with one of the high-risk virus types (and HPV 16 is by far the most common in the United States) are at higher risk for developing CIN than women who are not infected. Yet, few women who are infected with HPV 16 ever develop detectable CIN. Almost no one would argue for the routine use of HPV 16 testing of all women because it would add an enormous cost to the U.S. health care system. However, there might be a sub-group for whom such testing would be appropriate. For example, ter Harmsel et al suggest that women with ASCUS smears might represent an appropriate sub-group. Presumably, those women with ASCUS smears who were high-risk HPV type positive would continue to be frequently screened. Those who were HPV negative would stop the screenings and return to routine, once yearly Pap smear screening. Indeed, in any algorithm that uses HPV testing, those women who are HPV negative, regardless of their initial status, must be returned to annual screening for the test to be cost-effective.
The controversy will continue—probably far into the future. This current article certainly does not help us very much in our clinical practices. Rather, it is an interesting anecdote.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.